RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Application (Cancer, Cardiovascular, Genetic Disorders), End User - Global Forecast 2023-2030
The RNA Therapy Market size was estimated at USD 1.84 billion in 2022 and expected to reach USD 2.18 billion in 2023, at a CAGR 21.90% to reach USD 8.98 billion by 2030.
Market Segmentation & Coverage:
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the RNA Therapy Market.
- Based on Technology, market is studied across Enabled Technologies and Enabling Technologies. The Enabled Technologies is further studied across Inhibition, Labeling, Linear amplification, Microarrays, Purification, and qRT-PCR. The Enabling Technologies is further studied across RNA Antisense Technologies and RNA Interference Technologies. The RNA Antisense Technologies is further studied across MicroRNA and Small interfering RNA. The Enabling Technologies commanded largest market share of 63.41% in 2022, followed by Enabled Technologies.
- Based on Application, market is studied across Cancer, Cardiovascular, Genetic Disorders, Infectious Diseases, Kidney Diseases, Metabolic Disorders, Oncology, and Retinal Diseases. The Infectious Diseases commanded largest market share of 21.92% in 2022, followed by Oncology.
- Based on End User, market is studied across Academic Research, Diagnostics, and Drug Discovery & Development. The Drug Discovery & Development commanded largest market share of 72.54% in 2022, followed by Diagnostics.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.89% in 2022, followed by Europe, Middle East & Africa.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is an indispensable tool for assessing the RNA Therapy Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:
The Market Share Analysis offers invaluable insights into the vendor landscape RNA Therapy Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:
The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc..
The report offers valuable insights on the following aspects:
- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast for the RNA Therapy Market?
- Which products, segments, applications, and areas hold the highest investment potential in the RNA Therapy Market?
- What is the competitive strategic window for identifying opportunities in the RNA Therapy Market?
- What are the latest technology trends and regulatory frameworks in the RNA Therapy Market?
- What is the market share of the leading vendors in the RNA Therapy Market?
- Which modes and strategic moves are suitable for entering the RNA Therapy Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. RNA Therapy Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Target Specificity and Selectivity of Treatment and Diagnostics
- 5.1.1.2. Strategic Alliances & Funding Supported By Pharmaceutical Companies
- 5.1.1.3. Increased Potential of Virtual Drug Development Models
- 5.1.2. Restraints
- 5.1.2.1. Hurdles In Drug Delivery Commercialization
- 5.1.3. Opportunities
- 5.1.3.1. Increasing Usage in Cell-Based Cancer Immunotherapy
- 5.1.3.2. Significance of mRNA Medicine to Treat Deficiency and Genetic Disorders
- 5.1.3.3. Pipelined Clinical Trials of RNA-Based Therapeutics
- 5.1.4. Challenges
- 5.1.4.1. Risk Associated with Investment & Potential Outcomes
- 5.2. Market Segmentation Analysis
- 5.2.1. Technology: Enabled technologies elevating the advancements in RNA therapies
- 5.2.2. End User: Utilization of RNA therapies in drug discovery & development
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of COVID-19
- 5.5. Cumulative Impact of Russia-Ukraine Conflict
- 5.6. Cumulative Impact of High Inflation
- 5.7. Porter’s Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
- 5.8. Value Chain & Critical Path Analysis
- 5.9. Regulatory Framework
- 5.10. Client Customization
- 6. RNA Therapy Market, by Technology
- 6.1. Introduction
- 6.2. Enabled Technologies
- 6.3.1. Inhibition
- 6.3.2. Labeling
- 6.3.3. Linear amplification
- 6.3.4. Microarrays
- 6.3.5. Purification
- 6.3.6. qRT-PCR
- 6.3. Enabling Technologies
- 6.4.1. RNA Antisense Technologies
- 6.4.2.1. MicroRNA
- 6.4.2.2. Small interfering RNA
- 6.4.2. RNA Interference Technologies
- 7. RNA Therapy Market, by Application
- 7.1. Introduction
- 7.2. Cancer
- 7.3. Cardiovascular
- 7.4. Genetic Disorders
- 7.5. Infectious Diseases
- 7.6. Kidney Diseases
- 7.7. Metabolic Disorders
- 7.8. Oncology
- 7.9. Retinal Diseases
- 8. RNA Therapy Market, by End User
- 8.1. Introduction
- 8.2. Academic Research
- 8.3. Diagnostics
- 8.4. Drug Discovery & Development
- 9. Americas RNA Therapy Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific RNA Therapy Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa RNA Therapy Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Agreement, Collaboration, & Partnership
- 12.3.1.1. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics
- 12.3.2. Investment & Funding
- 12.3.2.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
- 12.3.2.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Alnylam Pharmaceuticals, Inc.
- 13.1.2. Arbutus Biopharma Corporation
- 13.1.3. Arcturus Therapeutics Holdings Inc.
- 13.1.4. Arrowhead Pharmaceuticals, Inc.
- 13.1.5. AstraZeneca PLC
- 13.1.6. Benitec Biopharma Limited
- 13.1.7. Biogen Inc.
- 13.1.8. BioNTech SE
- 13.1.9. Cartesian Therapeutics, Inc.
- 13.1.10. Cenix BioScience GmbH
- 13.1.11. Deep Genomics
- 13.1.12. Eli Lilly and Company
- 13.1.13. F. Hoffmann-La Roche AG
- 13.1.14. GSK PLC
- 13.1.15. Ionis Pharmaceuticals, Inc.
- 13.1.16. Laronde
- 13.1.17. MiNA Therapeutics Limited
- 13.1.18. Moderna, Inc.
- 13.1.19. NeuBase Therapeutics, Inc.
- 13.1.20. Nordic Nanovector ASA
- 13.1.21. Novartis AG
- 13.1.22. Novo Nordisk A/S
- 13.1.23. Nutcracker Therapeutics, Inc.
- 13.1.24. ProQR Therapeutics N.V.
- 13.1.25. Sanofi S.A.
- 13.1.26. Silence Therapeutics PLC
- 13.1.27. Sirnaomics, Inc.
- 13.1.28. Triplet Therapeutics, Inc.
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook